View in EDS

Developing low-carbon metered-dose inhalers: effects of propellant HFA-152a on mucociliary clearance and bronchoconstriction in two Phase 1 randomised trials.

Saved in:
Bibliographic Details
Title: Developing low-carbon metered-dose inhalers: effects of propellant HFA-152a on mucociliary clearance and bronchoconstriction in two Phase 1 randomised trials.
Authors: Singh D; Centre for Respiratory Medicine and Allergy, Institute of Inflammation and Repair, University of Manchester, Manchester University NHS Foundation Trust, Manchester, UK; Medicines Evaluation Unit, an IQVIA Business, Manchester, UK., Poggesi I; Clinical Pharmacology, Modeling and Simulation, GSK, Verona, Italy., Weng S; Respiratory Biostatistics, GSK, Stevenage, UK., Slade D; Respiratory Clinical Research Unit, GSK, Collegeville, PA, USA., Clow L; Respiratory, Immunology & Inflammation Research Unit (RIIRU) Medicine Development Leaders, GSK, Stevenage, UK., Patterson A; Clinical Imaging, Clinical Pharmacology and Quantitative Medicine, GSK, Stevenage, UK., McKenzie L; Quotient Sciences, Nottingham, UK., Brickhill B; Quotient Sciences, Nottingham, UK., Roe C; Quotient Sciences, Nottingham, UK., Ibrahimov E; Global Clinical Operations, GSK, Mississauga, ON, Canada., van der Palen J; Department of Epidemiology, Medisch Spectrum Twente, Enschede, the Netherlands; Section Cognition, Data and Education, Faculty of Behavioural, Management and Social Sciences, University of Twente, Enschede, the Netherlands., Donald A; Development Biostatistics, GSK, Collegeville, PA, USA., Plank M; Global Medical Affairs, General Medicines, GSK, Gold Coast, Australia. Electronic address: maximilian.x.plank@gsk.com.
Source: Respiratory medicine [Respir Med] 2026 Oct; Vol. 262, pp. 109053. Date of Electronic Publication: 2026 Jul 21.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 8908438 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-3064 (Electronic) Linking ISSN: 09546111 NLM ISO Abbreviation: Respir Med Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42480626
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Developing low-carbon metered-dose inhalers: effects of propellant HFA-152a on mucociliary clearance and bronchoconstriction in two Phase 1 randomised trials.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Singh+D%22">Singh D</searchLink>; Centre for Respiratory Medicine and Allergy, Institute of Inflammation and Repair, University of Manchester, Manchester University NHS Foundation Trust, Manchester, UK; Medicines Evaluation Unit, an IQVIA Business, Manchester, UK.<br /><searchLink fieldCode="AU" term="%22Poggesi+I%22">Poggesi I</searchLink>; Clinical Pharmacology, Modeling and Simulation, GSK, Verona, Italy.<br /><searchLink fieldCode="AU" term="%22Weng+S%22">Weng S</searchLink>; Respiratory Biostatistics, GSK, Stevenage, UK.<br /><searchLink fieldCode="AU" term="%22Slade+D%22">Slade D</searchLink>; Respiratory Clinical Research Unit, GSK, Collegeville, PA, USA.<br /><searchLink fieldCode="AU" term="%22Clow+L%22">Clow L</searchLink>; Respiratory, Immunology & Inflammation Research Unit (RIIRU) Medicine Development Leaders, GSK, Stevenage, UK.<br /><searchLink fieldCode="AU" term="%22Patterson+A%22">Patterson A</searchLink>; Clinical Imaging, Clinical Pharmacology and Quantitative Medicine, GSK, Stevenage, UK.<br /><searchLink fieldCode="AU" term="%22McKenzie+L%22">McKenzie L</searchLink>; Quotient Sciences, Nottingham, UK.<br /><searchLink fieldCode="AU" term="%22Brickhill+B%22">Brickhill B</searchLink>; Quotient Sciences, Nottingham, UK.<br /><searchLink fieldCode="AU" term="%22Roe+C%22">Roe C</searchLink>; Quotient Sciences, Nottingham, UK.<br /><searchLink fieldCode="AU" term="%22Ibrahimov+E%22">Ibrahimov E</searchLink>; Global Clinical Operations, GSK, Mississauga, ON, Canada.<br /><searchLink fieldCode="AU" term="%22van+der+Palen+J%22">van der Palen J</searchLink>; Department of Epidemiology, Medisch Spectrum Twente, Enschede, the Netherlands; Section Cognition, Data and Education, Faculty of Behavioural, Management and Social Sciences, University of Twente, Enschede, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Donald+A%22">Donald A</searchLink>; Development Biostatistics, GSK, Collegeville, PA, USA.<br /><searchLink fieldCode="AU" term="%22Plank+M%22">Plank M</searchLink>; Global Medical Affairs, General Medicines, GSK, Gold Coast, Australia. Electronic address: maximilian.x.plank@gsk.com.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228908438%22">Respiratory medicine</searchLink> [Respir Med] 2026 Oct; Vol. 262, pp. 109053. <i>Date of Electronic Publication: </i>2026 Jul 21.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>8908438 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1532-3064 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2209546111%22">09546111 </searchLink><i>NLM ISO Abbreviation: </i>Respir Med <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42480626
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.rmed.2026.109053
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 109053
    Titles:
      – TitleFull: Developing low-carbon metered-dose inhalers: effects of propellant HFA-152a on mucociliary clearance and bronchoconstriction in two Phase 1 randomised trials.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Singh D
      – PersonEntity:
          Name:
            NameFull: Poggesi I
      – PersonEntity:
          Name:
            NameFull: Weng S
      – PersonEntity:
          Name:
            NameFull: Slade D
      – PersonEntity:
          Name:
            NameFull: Clow L
      – PersonEntity:
          Name:
            NameFull: Patterson A
      – PersonEntity:
          Name:
            NameFull: McKenzie L
      – PersonEntity:
          Name:
            NameFull: Brickhill B
      – PersonEntity:
          Name:
            NameFull: Roe C
      – PersonEntity:
          Name:
            NameFull: Ibrahimov E
      – PersonEntity:
          Name:
            NameFull: van der Palen J
      – PersonEntity:
          Name:
            NameFull: Donald A
      – PersonEntity:
          Name:
            NameFull: Plank M
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 10
              Text: 2026 Oct
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1532-3064
          Numbering:
            – Type: volume
              Value: 262
          Titles:
            – TitleFull: Respiratory medicine
              Type: main
ResultId 1